Evidence‑Based Management of POEMS Syndrome

1. First‑Line Treatment Selection Based on Disease Extent

• Localized disease (1–3 sclerotic bone lesions, no bone‑marrow involvement) – definitive radiation therapy yields 97 % 4‑year overall survival and 52 % 4‑year failure‑free survival. (prospective data) 1
• Disseminated disease (diffuse sclerotic lesions or marrow involvement) – systemic chemotherapy followed by autologous stem‑cell transplantation (ASCT) in eligible patients is the recommended approach. (expert consensus) 1

2. Radiation Therapy for Localized Disease

• Radiation alone improves symptoms in 50–70 % of patients with a solitary plasmacytoma. (prospective series) 1
• In patients without marrow involvement and with limited bone lesions, radiation is curative. (observational data) 1
• Large bone lesions may require adjuvant radiation approximately 6 months after chemotherapy. (clinical practice) 1

3. Systemic Therapy for Disseminated Disease

3.1 Preferred First‑Line Regimens

• Melphalan + dexamethasone achieves an 81 % hematologic response rate and 100 % neuropathy improvement in prospective trials. (high‑level evidence) 1
• Lenalidomide + dexamethasone is preferred for patients with pre‑existing severe neuropathy because it carries a lower neurotoxicity risk. (prospective and guideline data) [1][2]
• A French prospective trial of lenalidomide/dexamethasone (2 induction cycles followed by high‑dose therapy or radiation, or 9 cycles followed by 12 cycles of lenalidomide monotherapy) demonstrated rapid neurologic responses. (prospective trial) 1

3.2 Agents to Avoid or Use with Extreme Caution

• Thalidomide‑based regimens should be avoided as first‑line therapy due to a high risk of worsening neuropathy. (expert consensus) 1
• Bortezomib‑based combinations are not recommended as first‑line despite an 81 % hematologic response, because of significant neuropathy risk. (expert consensus) 1
• The European Myeloma Network advises caution with bortezomib because of neurotoxicity; it should be reserved for patients who have failed other therapies or who have renal dysfunction where benefit outweighs risk. (guideline) [1][2]
• Bevacizumab is not recommended despite VEGF reduction, as several treatment‑related deaths have been reported. (expert consensus) 1

4. Autologous Stem‑Cell Transplantation (ASCT)

• ASCT should be offered to eligible younger patients with disseminated disease after induction chemotherapy, resulting in 100 % clinical improvement and excellent long‑term outcomes. (prospective data) 1
• Progression‑free survival after ASCT is 98 % at 1 year, 94 % at 2 years, and 75 % at 5 years. (prospective cohort) 1

5. Timeline Expectations for Response

• Neurologic improvement lags behind hematologic response; maximal neurologic recovery is typically observed 2–3 years after successful therapy. (prospective observation) 1
• Optimal FDG‑PET response may be delayed 6–12 months after treatment initiation. (prospective observation) 1

6. Monitoring Parameters

• Serum VEGF levels should be measured regularly as a marker of disease activity and treatment response. (expert consensus) 1
• VEGF is markedly elevated in POEMS syndrome and correlates with disease activity. (observational study) 2
• Melphalan‑dexamethasone achieved a 100 % VEGF response in prospective trials. (prospective data) 1

7. Common Pitfalls to Avoid

• Radiation alone is insufficient for disseminated disease; systemic therapy is mandatory. (prospective data) 1
• Patients treated with radiation only had inferior progression‑free and overall survival, largely because they were more ill at treatment start. (prospective data) 1
• Do not discontinue therapy prematurely due to lack of immediate neurologic improvement; the expected lag does not indicate treatment failure. (expert consensus) 1

Treatment of POEMS Syndrome

Introduction to POEMS Syndrome Treatment

• The American College of Hematology recommends radiation therapy as the definitive first-line treatment for POEMS syndrome with localized disease, achieving long-lasting responses in the majority of patients 3, 4
• For disseminated disease, systemic chemotherapy is required, with melphalan-dexamethasone or lenalidomide-dexamethasone as preferred regimens, followed by autologous stem cell transplantation (ASCT) in eligible patients 3, 4

Treatment Algorithm Based on Disease Extent

• Radiation therapy is the treatment of choice for patients with solitary or limited sclerotic bone lesions without bone marrow involvement, achieving 97% 4-year overall survival and 52% 4-year failure-free survival in retrospective analyses 3, 4
• Improvement occurs in 50-70% of patients treated with radiation alone 3
• Melphalan-dexamethasone achieves 81% hematologic response and 100% improvement in neuropathy in prospective trials 3

Autologous Stem Cell Transplantation

• ASCT should be offered to eligible patients with disseminated disease after induction chemotherapy, achieving 100% clinical improvement in transplant-eligible patients 3, 4

Expected Timeline of Response

• Neurologic improvement significantly lags behind hematologic response, with maximum neurologic response expected after 2-3 years of successful therapy 3
• Optimal response on FDG-PET may lag by 6-12 months after treatment 3

Agents to Avoid

• Thalidomide-based regimens should be avoided due to high neurotoxicity risk that can worsen pre-existing neuropathy 3
• Bortezomib-based combinations are not recommended as first-line due to induced neuropathy risk, despite high response rates 3, 5

Monitoring and Supportive Care

• Serum VEGF levels should be monitored as a marker of disease activity and treatment response 3, 6
• Endocrinopathy management should address thyroid, adrenal, and gonadal dysfunction 6
• Thrombotic risk management should monitor for thrombocytosis and consider prophylaxis 3, 6
• Pulmonary function and cardiac assessment should include regular monitoring with pulmonary function tests and echocardiography 3, 6